The IFN pathway, particularly well-documented for IFN-α, has emerged as a major driver of several autoimmune rheumatic diseases encompassing, but not restricted to, systemic lupus erythematosus (SLE) [98], Sjogren’s syndrome (pSS) [99], systemic sclerosis (SSc) [100], and dermatomyositis (DM) [101]. Here, IFNA1 is linked to systemic sclerosis.